Wezlana
Dec 01, 2023
Could Amgen’s Biosimilar Wezlana Pose a Challenge to Johnson & Johnson’s Stelara
The FDA recently approved Amgen’s Wezlana (ustekinumab-auub) for various inflammatory conditions, marking the first biosimilar approval referencing the popular J&J drug Stelara (ustekinumab). Wezlana, mirroring its reference product, is approved for treating multiple inflammatory diseases in adults, including m...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
